Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On July 22, 2025, Telix disclosed that it received a subpoena from the U.S. Securities and Exchange Commission, which is seeking various documents and information related to the company's disclosures about its prostate cancer therapeutic candidates [2]. - Following the news of the subpoena, Telix's American Depositary Receipt (ADR) price fell by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a long history of fighting for the rights of victims of securities fraud and corporate misconduct [3].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX